Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 891-913

  Cavassini, Matthias L ^a   D'Acremont, Valérie ^b   Furrer, Hansjakob ^c   Genton, Blaise ^b,d   Tarr, Philip E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Antiretroviral therapy; Drug interactions; HIV; Malaria; Pharmacological interactions; Prevention; Travel; Traveller's diarrhoea; Tropics; Vaccines

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ASTEMIZOLE; ATAZANAVIR; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; BCG VACCINE; BROMAZEPAM; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; DIPLOID CELL VACCINE; DOXYCYCLINE; EFAVIRENZ; ERGOTAMINE DERIVATIVE; FLUCONAZOLE; GARLIC EXTRACT; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERICUM PERFORATUM EXTRACT; IMIDAZOLE; INDINAVIR; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LEVOFLOXACIN; LIVE VACCINE; LOPERAMIDE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LORAZEPAM; MALARIA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEFLOQUINE; MENCEVAX; MENINGOCOCCUS VACCINE; MERIEUX; MIDAZOLAM; MULTIVITAMIN; NELFINAVIR; ORAL POLIOMYELITIS VACCINE; OXAZEPAM; PHOSPHODIESTERASE INHIBITOR; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; QUININE; RABIES VACCINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TEMAZEPAM; TERFENADINE; TICK BORNE ENCEPHALITIS VACCINE; TYPHERIX; TYPHIM V; TYPHOID VACCINE; YELLOW FEVER VACCINE;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; CANDIDIASIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG POTENTIATION; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FOLLOW UP; HEART ARRHYTHMIA; HEPATITIS A; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFLUENZA; LIMB ISCHEMIA; LIVER TOXICITY; LUNG INFECTION; LYMPHADENITIS; LYMPHOCYTE COUNT; MALARIA; MEASLES; MENINGOCOCCOSIS; MENINGOENCEPHALITIS; MENTAL DISEASE; MUMPS; NEUROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PNEUMONIA; POLIOMYELITIS; PRIAPISM; QT PROLONGATION; RABIES; RESPIRATION DEPRESSION; REVIEW; RUBELLA; TICK BORNE ENCEPHALITIS; TRAVEL; TRAVELLER DIARRHEA; TUBERCULOSIS; TYPHOID FEVER; VASOCONSTRICTION; YELLOW FEVER;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MALARIA; TRAVEL; VACCINES;

EID: 21744462074     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.891     Document Type: Review

References (180)

1. CASTELLI F, PIZZOCOLO C: The traveler with HIV In: Travel Medicine. Keystone JS, Kozarsky P, Freedman DO, Nothdurft HD Connor BA (Eds), Elsevier Science (2004):257-266.
2. KEMPER CA, LINETT A, KANE C, DERESINSKI SC: Travels with HIV: the compliance and health of HIV-infected adults who travel. Int. J. STD AIDS (1997) 8(1):44-49.
3. BOGGILD AK, SANO M, HUMAR A, SALIT I, GILMAN M, KAIN KC: Travel patterns and risk behavior in solid organ transplant recipients. J. Tavel. Med. (2004) 11 (1):37-43.
4. FURRER H, CHAN P, WEBER R, EGGER M: Increased risk of wasting syndrome in HIV-infected travellers: prospective multicentre study. Trans. R. Soc. Trop. Med. Hyg. (2001) 95(5):484-486.
5. KARP CL: Preparation of the HIV-infected traveler to the tropics. Curr. Infect. Dis. Rep. (2001) 3(1):50-58.
6. MCKENZIE R: Travel advice for HIV-infected individuals. Hopkins HIV Rep. (2004) 16(3):9-12.
7. CASTELLI F, PATRONI A: The human immunodeficiency virus-infected traveler. Clin. Infect. Dis. (2000) 31(6):1403-1408.
8. VAN GA, KOZARSKY P, COLEBUNDERS R: Adult travelers with HIV infection. J. Travel. Med. (1997) 4(3):136-143.
9. MILENO MD, BIA FJ: The compromised traveler. Infect. Dis. Clin. North Am. (1998) 12(2):369-412.
10. SIMONS FM, COBELENS FG, DANNER SA: Common health problems in HIV-infected travelers to the (sub)tropics. J. Travel. Med. (1999) 6(2):71-75.
11. STEFFEN R, RICKENBACH M, WILHELM U, HELMINGER A, SCHAR M: Health problems after travel to developing countries. J. Infect. Dis. (1987) 156(1):84-91.
12. EGGER M, MAY M, CHENE G et al.: prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 360(9327):119-129
13. RYAN ET, KAIN KC: Health advice and immunizations for travelers. N. Engl. J. Med. (2000) 342(23):1716-1725.
14. BLAIR DC: A week in the life of a travel clinic. Clin. Microbiol. Rev. (1997) 10(4):650-673.
15. BACANER N, STAUFFER B, BOULWARE DR, WALKER PF, KEYSTONE JS: Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA (2004) 291 (23):2856-2864.
16. FENTON KA, CHINOUYA M, DAVIDSON O, COPAS A: HIV transmission risk among sub-Saharan Africans in London travelling to their countries of origin. AIDS (2001) 15(11):1442-1445.
17. CABADA MM, ECHEVARRIA JI, SEAS CR et al: Sexual behavior of international travelers visiting Peru. Sex. Transm. Dis. (2002) 29(9):510-513.
18. BELLIS MA, HUGHES K, THOMSON R, BENNETT A: Sexual behaviour of young people in international tourist resorts. Sex. Transm. Infect. (2004) 80(1):43-47.
19. APOSTOLOPOULOS Y, SONMEZ S, YU CH: HIV-risk behaviours of American spring break vacationers: a case of situational disinhibition? Int. J. STD AIDS (2002) 13(11):733-743.
20. MEMISH ZA, OSOBA AO: Sexually transmitted diseases and travel. Int. J. Antimicrob. Agents (2003) 21(2):131-134.
21. GEHRING TM, WIDMER J, KLEIBER D, STEFFEN R: Are preventive HIV interventions at airports effective? J. Travel. Med. (1998) 5(4):205-209.
22. JOST S, BERNARD MC, KAISER L et al.: A patient with HIV-1 superinfection. N. Engl. J. Med. (2002) 347(10):731-736.
23. YERLY S, JOST S, MONNAT M et al.: HIV-1 co/super-infection in intravenous drug users. AIDS (2004) 18(10):1413-1421.
24. ELLIOTT R: Criminal law and HIV transmission/exposure: three new cases. Can. HIV. AIDS Policy Law Rev. (2002) 6(3):64-66.
25. GALLETLY CL, PINKERTON SD: Toward rational criminal HIV exposure laws. J. Law Med. Ethics (2004) 32(2):327-332.
26. BIRD SM, BROWN AJ: Criminalisation of HIV transmission: implications for public health in Scotland. Br. Med. J. (2001) 323(7322):1174-1177.
27. SULKOWSKI MS, CHAISSON RE, KARP CL, MOORE RD, MARGOLICK JB, QUINN TC: The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) Type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J. Infect. Dis. (1998) 178(6):1642-1648.
28. KARP CL, NEVA FA: Tropical infectious diseases in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (1999) 28(5):947-963.
29. BUCHACZ K, PATEL P, TAYLOR M et al.: Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS (2004) 18(15):2075-2079.
30. WATT G, KANTIPONG P, JONGSAKUL K: Decrease in human immunodeficiency virus Type 1 load during acute dengue fever. Clin. Infect. Dis. (2003) 36(8):1067-1069.
31. CARR A, COOPER DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356(9239):1423-1430.
32. FELLAY J, BOUBAKER K, LEDERGERBER B et al.: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet (2001) 358(9290):1322-1327.
33. ROBERTSON SM, PENZAK SR, PAU AK: Drug interactions in the management of HIV infection. Expert. Opin. Pharmacother. (2005) 6(2):233-253.
34. ROMANELLI F, SMITH KM: Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. Ann. Pharmacother. (2004) 38(6):1024-1030.
35. ANTONIOU T, TSENG AL: Interactions between recreational drugs and antiretroviral agents. Ann. Pharmacother. (2002) 36(10):1598-1613.
36. FAIRFIELD KM, EISENBERG DM, DAVIS RB, LIBMAN H, PHILLIPS RS: Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch. Intern. Med. (1998) 158(20):2257-2264.
37. HSIAO AF, WONG MD, KANOUSE DE et al.: Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J. Acquir. Immune Defic. Syndr. (2003) 33(2):157-165.
38. PISCITELLI SC, BURSTEIN AH, CHAITT D, ALFARO RM, FALLOON J: Indinavir concentrations and St John's wort. Lancet (2000) 355(9203):547-548.
39. PISCITELLI SC, BURSTEIN AH, WELDEN N, GALLICANO KD, FALLOON J: The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. (2002) 34(2):234-238.
40. COLEBUNDERS R, NACHEGA J, VAN GA: Antiretroviral treatment and travel to developing countries. J. Travel Med. (1999) 6(1):27-31.
41. PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
42. KILBY JM, GOEPFERT PA, MILLER AP et al.: Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann. Intern. Med. (2000) 133(6):435-438.
43. RODRIGUEZ-BARRADAS MC, GROOVER JE, LACKE CE et al.: IgG antibody to pneumococcal capsular polysaccharide in human immunodeficiency virus-infected subjects: persistence of antibody in responders, revaccination in nonresponders, and relationship of immunoglobulin allotype to response. J. Infect. Dis. (1996) 173(6):1347-1353.
44. KROON FP, VAN DISSEL JT, DE JONG JC, VAN FR: Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS (1994) 8(4):469-476.
45. LEDERGERBER B, EGGER M, TELENTI A: AIDS-Related opportunistic illness and potent antiretroviral therapy. JAMA (2000) 283(20):2653-2654.
46. SUBRAMANIAM KS, SEGAL R, LYLES RH, RODRIGUEZ-BARRADAS MC, PIROFSKI LA: Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J. Infect. Dis. (2003) 187(5):758-768.
47. RODRIGUEZ-BARRADAS MC, ALEXANDRAKI I, NAZIR T et al.: Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin. Infect. Dis. (2003) 37(3):438-447.
48. BERKELHAMER S, BOROCK E, ELSEN C, ENGLUND J, JOHNSON D: Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin. Infect. Dis. (2001) 32(7):1090-1094.
49. VALDEZ H, SMITH KY, LANDAY A et al.: Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS (2000) 14(1):11-21.
50. LANGE CG, LEDERMAN MM, MEDVIK K et al.: Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS (2003) 17(14):2015-2023.
51. LEDERMAN HM, WILLIAMS PL, WU JW et al.: Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J. Infect. Dis. (2003) 188(12):1794-1803.
52. FEIKIN DR, ELIE CM, GOETZ MB et al.: Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine (2001) 20(3-4):545-553.
53. WALLACE MR, BRANDT CJ, EARHART KC et al.: Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin. Infect. Dis. (2004) 39(8):1207-1213.
54. KROON FP, VAN DISSEL JT, RAVENSBERGEN E, NIBBERING PH, VAN FR: Impaired antibody response after immunization of HIV-infected individuals wich the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). Vaccine (1999) 17(23-24):2941-2945.
55. KROON FP, VAN DISSEL JT, RAVENSBERGEN E, NIBBERING PH, VAN FR: Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine (2000) 19(7-8):886-894.
56. TASKER SA, TREANOR JJ, PAXTON WB, WALLACE MR: Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1999) 131(6):430-433.
57. REY D, KRANTZ V, PARTISANI M et al.: Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine (2000) 18(13):1161-1165.
58. KAPLAN JE, MASUR H, HOLMES KK: Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm. Rep. (2002) 51(RR-8):1-52.
59. GUNTHARD HF, WONG JK, SPINA CA et al.: Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J. Infect. Dis. (2000) 181(2):522-531.
60. KEMPER CA, HAUBRICH R, FRANK I et al.: Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J. Infect. Dis. (2003) 187(8):1327-1331.
61. SAFRIN S, RUSH JD, MILLS J: Influenza in patients with human immunodeficiency virus infection. Chest (1990) 98(1):33-37.
62. GOLDEN MP, SAJJAD Z, ELGART L: Influenza and human immunodeficiency virus infection: absence of HIV progression after acute influenza infection. Clin. Infect. Div. (2001) 32(9):1366-1370.
63. RADWAN HM, CHEESEMAN SH, LAI KK, ELLISON III RT: Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin. Infect. Dis. (2000) 31(2):604-606.
64. LIN JC, NICHOL KL: Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch. Intern. Med. (2001) 161(3):441-446.
65. NEUZIL KM, COFFEY CS, MITCHEL EF JR, GRIFFIN MR: Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J. Acquir. Immune. Defic. Syndr. (2003) 34(3):304-307.
66. FINE AD, BRIDGES CB, DE GUZMAN AM et al.: Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin. Infect. Dis. (2001) 32(12):1784-1791.
67. HARPER SA, FUKUDA K, UYEKI TM, COX NJ, BRIDGES CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2004) 53(RR-6):1-40.
68. MIOTTI PG, NELSON KE, DALLABETTA GA, FARZADEGAN H, MARGOLICK J, CLEMENTS ML: The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA (1989) 262(6):779-783.
69. IORIO AM, ALATRI A, FRANCISCI D et al.: Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine (1997) 15(1):97-102.
70. KING JC JR, TREANOR J, FAST PE et al.: Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J. Infect. Dis. (2000) 181(2):725-728.
71. STEFFEN R: Hepatitis A in travelers: the European experience. J. Infect. Dis. (1995) 171(Suppl. 1):S24-S28.
72. LOSCHER T, KEYSTONE JS, STEFFEN R: Vaccination of travelers against hepatitis A and B. J. Travel. Med. (1999) 6(2):107-114.
73. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP): MWWR Recomm. Rep. (1999) 48(RR-12):1-37.
74. IDA S, TACHIKAWA N, NAKAJIMA A et al.: Influence of human immunodeficiency virus Type 1 infection on acute hepatitis A virus infection. Clin. Infect. Dis. (2002) 34(3):379-385.
75. FONQUERNIE L, MEYNARD JL, CHARROIS A, DELAMARE C, MEYOHAS MC, FROTTIER J: Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (2001) 32(2):297-299.
76. KAHN J: Preventing hepatitis A and hepatitis B virus infections among men who have sex with men. Clin. Infect. Dis. (2002) 35(11):1382-1387.
77. STUDER S, JOLLER-JEMELKA HI, STEFFEN R, GROB PJ: Prevalence of hepatitis A antibodies in Swiss travellers. Eur. J. Epidemiol. (1993) 9(1):50-54.
78. VAN DP, BANATVALA J, FAY O et al.: Hepatitis A booster vaccination: is there a need? Lancet (2003) 362(9389):1065-1071.
79. NEILSEN GA, BODSWORTH NJ, WATTS N: Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J. Infect. Dis. (1997) 176(4):1064-1067.
80. BODSWORTH NJ, NEILSEN GA, DONOVAN B: The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up. AIDS (1997) 11(6):747-749.
81. KRAUSE DS: Hepatitis A vaccine and travel departure. Clin. Infect. Dis. (1998) 26(4):1018.
82. MOSS WJ, CLEMENTS CJ, HALSEY NA: Immunization of children at risk of infection with human immunodeficiency virus. Bull. World Health Organ. (2003) 81(1):61-70.
83. ION-NEDELCU N, DOBRESCU A, STREBEL PM, SUTTER RW: Vaccine-associated paralytic poliomyelitis and HIV infection. Lancet (1994) 343(8888):51-52.
84. Prevention of poliomyelitis: recommendations for use of only inactivated poliovirus vaccine for routine immunization. Committee on Infectious Diseases. American Academy of Pediatrics. Pediatrics (1999) 104(6):1404-1406.
85. MATHISEN GE, ALLEN AD: Inactivated polio vaccine hyperimmunization in adults with HIV disease: a placebo-controlled study. AIDS (1992) 6(7):737-738.
86. BARBI M, BIFFI MR, BINDA S et al.: Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid. AIDS (1992) 6(12):1465-1469.
87. KROON FP, VAN DISSEL JT, LABADIE J, VAN LOON AM, VAN FR: Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin. Infect. Dis. (1995) 21(5):1197-1203.
88. PREVOTS DR, BURR RK, SUTTER RW, MURPHY TV: Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (2000) 49(RR-5):1-22.
89. GOTUZZO E, FRISANCHO O, SANCHEZ J et al.: Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area. Arch. Intern. Med. (1991) 151(2):381-382.
90. PARRY CM, HIEN TT, DOUGAN G, WHITE NJ, FARRAR JJ: Typhoid fever. N. Engl. J. Med. (2002) 347(22):1770-1782.
91. Human rabies prevention-United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (1999) 48 (RR-1):1-21.
92. WILDE H, BRIGGS DJ, MESLIN FX, HEMACHUDHA T, SITPRIJA V: Rabies update for travel medicine advisors. Clin. Infect. Dis. (2003) 37(1):96-100.
93. THISYAKORN U, PANCHAROEN C, RUXRUNGTHAM K et al.: Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus Type 1. Clin. Infect. Dis. (2000) 30(1):218.
94. TANTAWICHIEN T, JAIJAROENSUP W, KHAWPLOD P, SITPRIJA V: Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin. Infect. Dis. (2001) 33(10):E122-E124.
95. PANDEY P, SHLIM DR, CAVE W, SPRINGER MF: Risk of possible exposure to rabies among tourists and foreign residents in Nepal. J. Travel. Med. (2002) 9(3):127-131.
96. KENGSAKUL K, SATHIRAPONGSASUTI K, PUNYAGUPTA S: Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai. (2002) 85(1):131-134.
97. GOUJON C, TOHR M, FEUILLE V, GOULAUD JP, DUPONT B, SANSONETTI P: Good tolerance and efficacy of yellow fever vaccine among subjects carriers of human immunodeficiency virus. 4th International Conference on Travel Medicine, Acapulco, Mexico (1995) (Abstr. 32).
98. RECEVEUR MC, THIEBAUT R, VEDY S, MALVY D, MERCIE P, BRAS ML: Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin. Infect. Dis. (2000) 31(3):E7-E8.
99. WILSON ME, VON REYN CF, FINEBERG HV: Infections in HIV-infected travelers: risks and prevention. Ann. Intern. Med. (1991) 114(7):582-592.
100. TATTEVIN P, DEPATUREAUX AG, CHAPPLAIN JM et al.: Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS (2004) 18(5):825-827.
101. SIBAILLY TS, WIKTOR SZ, TSAI TF et al.: Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus Type 1. Pediatr. Infect. Dis. J. (1997) 16(12):1177-1179.
102. BARWICK R: History of thymoma and yellow fever vaccination. Lancet (2004) 364(9438):936.
103. KITCHENER S: Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine (2004) 22(17-18):2103-2105.
104. SPANISH AGENCY FOR MEDICINES AND HEALTH CARE PRODUCTS: A death associated with yellow fever vaccination reported in Spain. Eurosurveillance weekly (2004) 8(45):1-2.
105. MARTIN M, TSAI TF, CROPP B et al.: Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet (2001) 358(9276):98-104.
106. VASCONCELOS PF, LUNA EJ, GALLER R et al.: Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet (2001) 358(9276):91-97.
107. POLAND JD, CALISHER CH, MONATH TP, DOWNS WG, MURPHY K: Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ. (1981) 59(6):895-900.
108. CETRON MS, MARFIN AA, JULIAN KG et al.: Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm. Rep. (2002) 51 (RR-17): 1-11.
109. VUKSHICH ON, HARPAZ R, REDD SB, PAPANIA MJ: International importation of measles virus - United States, 1993-2001. J. Infect. Dis. (2004) 189(Suppl. 1):S48-S53.
110. WATSON JC, HADLER SC, DYKEWICZ CA, REEF S, PHILLIPS L: Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (1998) 47(RR-8):1-57.
111. SHA BE, HARRIS AA, BENSON CA et al.: Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults. J. Infect. Dis. (1991) 164(5):973-975.
112. WALLACE MR, HOOPER DG, GRAVES SJ, MALONE JL: Measles seroprevalence and vaccine response in HIV-infected adults. Vaccine (1994) 12(13):1222-1224.
113. ATKINSON WL, PICKERING LK, SCHWARTZ B, WENIGER BG, ISKANDER JK, WATSON JC: General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Familv Physicians (AAFP). MMWR Recomm. Rep. (2002) 51(RR-2):1-35.
114. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR Morb. Mortal. Wkly. Rep. (1996) 45(28):603-606.
115. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. (1996) 45(RR-12):1-35.
116. Measles immunization in HIV-infected children. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Pediatric AIDS. Pediatrics (1999) 103(5 Pt 1):1057-1060.
117. BRINDLE R, SIMANI P, NEWNHAM R, WAIYAKI P, GILKS C: No association between meningococcal disease and human immunodeficiency virus in adults in Nairobi, Kenya, Trans. R. Soc. Trop. Med. Hyg. (1991) 85(5):651.
118. MORLA N, GUIBOURDENCHE M, RIOU JY: Neisseria spp. and AIDS. J. Clin. Microbiol. (1992) 30(9):2290-2294.
119. NITTA AT, DOUGLAS JM, ARAKERE G, EBENS JB: Disseminated meningococcal infection in HIV-seropositive patients. AIDS (1993) 7(1):87-90.
120. Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia-United States, 2000. MMWR Morb. Mortal. Wkly. Rep. (2000) 49(16):345-346.
121. RENNELS M, KING J, JR., RYALL R, PAPA T, FROESCHLE J: Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. (2004) 23(5):429-435.
122. CAMPBELL JD, EDELMAN R, KING JC JR, PAPA T, RYALL R, RENNELS MB: Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J. Infect. Dis. (2002) 186(12):1848-1851.
123. ROJANASUPHOT S, SHAFFER N, CHOTPITAYASUNONDH T et al.: Response to JE vaccine among HIV-infected children, Bangkok, Thailand. Southeast Asian J. Trop. Med. Public Health (1998) 29(3):443-450.
124. PLESNER AM, RONNE T: Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine (1997) 15(11):1239-1243.
125. RENDI-WAGNER P: Risk and prevention of tick-borne encephalitis in travelers. J. Travel. Med. (2004) 11(5):307-312.
126. PANASIUK B, PROKOPOWICZ D, PANASIUK A: Immunological response in HIV-positive patients vaccinated against tick-borne encephalitis. Infection (2003) 31(1):45-46.
127. PORTER JD: Mycobacteriosis and HIV infection: the new public health challenge. J. Antimicrob. Chemother. (1996) 37(Suppl. B):113-120.
128. RIEDER HL: Risk of travel-associated tuberculosis. Clin. Infect. Dis. (2001) 33(8):1393-1396.
129. COBELENS FG, VAN DH, DRAAYER-JANSEN IW et al.: Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet (2000) 356(9228):461-465.
130. ARONSON NE, SANTOSHAM M, COMSTOCK GW et al.: Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA (2004) 291(17):2086-2091.
131. EDWARDS KM, KERNODLE DS: Possible hazards of routine bacillus Calmette-Guerin immunization in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. (1996) 15(9):836-838.
132. O'BRIEN KL, RUFF AJ, LOUIS MA et al.: Bacillus Calmette-Guerin complications in children born to HIV-1-infected women wich a review of the literature. Pediatrics (1995) 95(3):414-418.
133. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm. Rep. (1996) 45(RR-4):1-18.
134. WHITWORTH J, MORGAN D, QUIGLEY M et al.: Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet (2000) 356(9235):1051-1056.
135. FRANCESCONI P, FABIANI M, DENTE MG et al.: HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS (2001) 15(18):2445-2450.
136. FRENCH N, NAKIYINGI J, LUGADA E, WATERA C, WHITWORTH JA, GILKS CF: Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS (2001) 15(7):899-906.
137. MWAPASA V, ROGERSON SJ, MOLYNEUX ME et al.: The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS (2004) 18(7):1051-1059.
138. MOUNT AM, MWAPASA V, ELLIOTT SR et al.: Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet (2004) 363(9424):1860-1867.
139. GRIMWADE K, FRENCH N, MBATHA DD, ZUNGU DD, DEDICOAT M, GILKS CF: HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS (2004) 18(3):547-554.
140. KAMYA MR, KIGONYA CN, MCFARLAND W: HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children. AIDS (2001) 15(9):1187-1188.
141. BIRKU Y, MEKONNEN E, BJORKMAN A, WOLDAY D: Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection created with artemisinin. Ethiop. Med. J. (2002) 40(Suppl. 11):117-126.
142. PISELL TL, HOFFMAN IF, JERE CS et al.: Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. AIDS (2002) 16(11):1503-1509.
143. HOFFMAN IF, JERE CS, TAYLOR TE et al.: The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS (1999) 13(4):487-494.
144. NATHOO S, SERGHIDES L, KAIN KC: Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet (2003) 362(9389):1039-1041.
145. SKINNER-ADAMS TS, MCCARTHY JS, GARDINER DL, HILTON PM, ANDREWS KT: Antiretrovirals as antimalarial agents. J. Infect. Dis. (2004) 190(11):1998-2000.
146. LEE W, KIM RB: Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol. (2004) 44: 137-166.
147. KHALIQ Y, GALLICANO K, TISDALE C, CARIGNAN G, COOPER C, MCCARTHY A: Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br. J. Clin. Pharmacol. (2001) 51(6):591-600.
148. SCHIPPERS EF, HUGEN PW, DEN HJ et al.: No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients. AIDS (2000) 14(17):2794-2795.
149. EMMANUEL A, GILLOTIN C, FARINOTTI REAL: Atovaquone suspension and indinavir have minimal pharmacokinetic interactions. 12th World AIDS conference, Geneva (1998)
150. TAYLOR WR, WHITE NJ: Antimalarial drug toxicity: a review. Drug Saf. (2004) 27(1):25-61.
151. ADACHI JA, OSTROSKY-ZEICHNER L, DUPONT HL, ERICSSON CD: Empirical antimicrobial therapy for traveler's diarrhea. Clin. Infect. Dis. (2000) 31(4):1079-1083.
152. DUPONT HL, ERICSSON CD: Prevention and treatment of traveler's diarrhea. N. Engl. J. Med. (1993) 328(25):1821-1827.
153. ERICSSON CD: Travelers' diarrhea. Epidemiology, prevention, and self-treatment. Infect. Dis. Clin. North Am. (1998) 12(2):285-303.
154. KOZICKI M, STEFFEN R, SCHAR M: 'Boil it, cook it, peel it or forget it': does this rule prevent travellers' diarrhoea? Int. J. Epidemiol. (1985) 14(1):169-172.
155. MATTILA L, SIITONEN A, KYRONSEPPA H, SIMULA I, I, PELTOLA H: Risk Behavior for Travelers' Diarrhea Among Finnish Travelers. J. Travel. Med. (1995) 2(2):77-84.
156. BACKER H: Water disinfection for international and wilderness travelers. Clin. Infect. Dis. (2002) 34(3):355-364.
157. GRUENEWALD R, BLUM S, CHAN J: Relationship between human immunodeficiency virus infection and salmonellosis in 20- to 59-year-old residents of New York City. Clin. Infect. Dis. (1994) 18(3):358-363.
158. EGLOFF N, OEHLER T, ROSSI M, NGUYEN XM, FURRER H: Chronic watery diarrhea due to co-infection with Cryptosporidium spp and Cyclospora cayetanensis in a Swiss AIDS patient traveling in Thailand. J. Travel Med. (2001) 8(3):143-145.
159. KEAN BH: The diarrhea of travelers to mexico. Summary of five-year study. Ann. Intern. Med. (1963) 59:605-614.
160. DE BG, HAHN S, BORWICK A: Antibiotic treatment for travellers' diarrhoea. Cochrane. Database Syst. Rev. (2000) (3):CD002242.
161. PETRUCCELLI BP, MURPHY GS, SANCHEZ JL et al.: Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J. Infect. Dis. (1992) 165(3):557-560.
162. FERNANDEZ GUERRERO ML, RAMOS JM, NUNEZ A, NUNEZ A, DE GM: Focal infections due to non-typhi Salmonella in patients with AIDS: report of 10 cases and review. Clin. Infect. Dis. (1997) 25(3):690-697.
163. ANGULO FJ, SWERDLOW DL: Bacterial enteric infections in persons infected with human immunodeficiency virus. Clin. Infect. Dis. (1995) 21(Suppl. 1):S84-S93.
164. GERMANI Y, MINSSART P, VOHITO M et al.: Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Am. J. Trop. Med. Hyg. (1998) 59(6):1008-1014.
165. KUSCHNER RA, TROFA AF, THOMAS RJ et al.: Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin. Infect. Dis. (1995) 21(3):536-541.
166. ADACHI JA, ERICSSON CD, JIANG ZD et al.: Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin. Infect. Dis. (2003) 37(9):1165-1171.
167. STEFFEN R: Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J. Travel. Med. (2001) 8(Suppl. 2):S34-S39.
168. DUPONT HL, JIANG ZD, ERICSSON CD et al.: Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin. Infect. Dis. (2001) 33(11):1807-1815.
169. BENSON CA, KAPLAN JE, MASUR H, PAU A, HOLMES KK: Treating opportunistic infections among HIV-exposed adults and adolescents. MMWR Recomm. Rep. (2004) 53(RR-15):1-112.
170. PAPE JW, VERDIER RI, BONCY M, BONCY J, JOHNSON WD JR: Cyclospora infection in adults infected with HIV. Clinical manifestations, treatment, and prophylaxis. Ann. Intern. Med. (1994) 121(9):654-657.
171. HIRSCHTICK RE, GLASSROTH J, JORDAN MC et al.: Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N. Engl. J. Med. (1995) 333(13):845-851.
172. EIGENMANN C, FLEPP M, BERNASCONI E et al.: Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis. Clin. Infect. Dis. (2003) 36(7):917-921.
173. SULLIVAN JH, MOORE RD, KERULY JC, CHAISSON RE: Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am. J. Respir. Crit. Care Med. (2000) 162(1):64-67.
174. SUPPARATPINYO K, KHAMWAN C, BAOSOUNG V, NELSON KE, SIRISANTHANA T: Disseminated Penicillium marneffei infection in southeast Asia. Lancet (1994) 344(8915):110-113.
175. JULANDER I, PETRINI B: Penicillium marneffei infection in a Swedish HIV-infected immunodeficient narcotic addict. Scand. J. Infect. Dis. (1997) 29(3):320-322.
176. MENS H, HOJLYNG N, ARENDRUP MC: Disseminated Penicillium marneffei sepsis in a HIV-positive Thai woman in Denmark. Scand. J. Infect. Dis. (2004) 36(6-7):507-509.
177. TANPHAICHITRA D: Tropical disease in the immunocompromised host: melioidosis and pythiosis. Rev. Infect. Dis. (1989) 11 (Suppl. 7):S1629-S1643.
178. CURRIE BJ, FISHER DA, HOWARD DM et al.: Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. (2000) 31(4):981-986.
179. KANAI K, KURATA T, AKKSILP S, AUWANIT W, CHAOWAGUL V, NAIGOWIT P: A preliminary survey for human immunodeficient virus (HIV) infections in tuberculosis and melioidosis patients in Ubon Ratchathani, Thailand. Jpn. J. Med. Sci. Biol. (1992) 45(5-6):247-253.
180. EGGER M, HIRSCHEL B, FRANCIOLI P et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br. Med. J. (1997) 315(7117):1194-1199.